

# Florent Malard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4058909/publications.pdf>

Version: 2024-02-01

97  
papers

4,261  
citations

101543

36  
h-index

128289

60  
g-index

99  
all docs

99  
docs citations

99  
times ranked

6086  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 443-449.	1.3	0
2	COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease. <i>Current Research in Translational Medicine</i> , 2022, 70, 103332.	1.8	1
3	Immune restoration therapy for multidrug-resistant CMV disease in an allogeneic stem cell transplant recipient. <i>Current Research in Translational Medicine</i> , 2022, 70, 103329.	1.8	2
4	Low incidence of hyperacute graft-versus-host disease (<sc>GVHD</sc>) with effective <sc>GVHD</sc> prophylaxis based on anti-thymocyte globulin. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
5	Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. <i>Blood Cancer Journal</i> , 2022, 12, 47.	6.2	19
6	Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 780-784.	2.5	1
7	Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 419-427.	1.3	9
8	Introduction to host microbiome symbiosis in health and disease. <i>Mucosal Immunology</i> , 2021, 14, 547-554.	6.0	95
9	Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?. <i>Current Research in Translational Medicine</i> , 2021, 69, 103273.	1.8	4
10	Venetoclax does not impair activated T-cell proliferation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1740-1742.	2.4	7
11	Letâ€™s reconstitute microbiota diversity. <i>Blood</i> , 2021, 137, 1442-1444.	1.4	3
12	Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective. <i>British Journal of Haematology</i> , 2021, 195, 495-506.	2.5	5
13	Comprehensive Review of AL amyloidosis: some practical recommendations. <i>Blood Cancer Journal</i> , 2021, 11, 97.	6.2	37
14	Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. <i>Current Research in Translational Medicine</i> , 2021, 69, 103283.	1.8	3
15	Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. <i>Nature Communications</i> , 2021, 12, 3084.	12.8	38
16	Increasing Donor Options in Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 1951-1954.	1.6	1
17	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. <i>JACC: CardioOncology</i> , 2021, 3, 250-259.	4.0	48
18	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. <i>Mucosal Immunology</i> , 2021, 14, 1127-1132.	6.0	9

#	ARTICLE	IF	CITATIONS
19	Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 142.	6.2	106
20	TFH cells in systemic sclerosis. <i>Journal of Translational Medicine</i> , 2021, 19, 375.	4.4	8
21	Outcome of allogeneic hematopoietic stem cell transplant recipients admitted to the intensive care unit with a focus on haploidentical graft and sequential conditioning regimen: results of a retrospective study. <i>Annals of Hematology</i> , 2021, 100, 2787-2797.	1.8	2
22	Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. <i>Frontiers in Oncology</i> , 2021, 11, 722436.	2.8	6
23	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
24	Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 452-460.	2.4	12
25	Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 586-594.	2.4	19
26	A novel mouse model of acute graft-versus-host disease based on chemotherapy conditioning and G-CSF mobilized graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 570-577.	2.4	3
27	Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do?. <i>British Journal of Haematology</i> , 2020, 188, 351-353.	2.5	2
28	Features of <i>Toxoplasma gondii</i> reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting. <i>Bone Marrow Transplantation</i> , 2020, 55, 93-99.	2.4	27
29	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 763-772.	2.4	16
30	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 377-382.	0.4	10
31	High-dose post-transplant cyclophosphamide impairs T cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. <i>Clinical and Translational Immunology</i> , 2020, 9, e1171.	3.8	9
32	Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 791-796.	0.4	6
33	Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience. <i>Cytotherapy</i> , 2020, 22, 445-449.	0.7	8
34	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906.	1.4	34
35	COVID-19 outcomes in patients with hematologic disease. <i>Bone Marrow Transplantation</i> , 2020, 55, 2180-2184.	2.4	138
36	Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. <i>Clinical and Translational Immunology</i> , 2020, 9, e1139.	3.8	70

#	ARTICLE	IF	CITATIONS
37	Acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2020, 395, 1146-1162.	13.7	343
38	Old dog, new trick: Trivalent arsenic as an immunomodulatory drug. <i>British Journal of Pharmacology</i> , 2020, 177, 2199-2214.	5.4	16
39	Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-inhibition. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1061-1072.	12.0	12
40	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
41	Management of patients with multiple myeloma during the COVID-19 pandemic. <i>Lancet Haematology</i> , the, 2020, 7, e435-e437.	4.6	39
42	Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. <i>Leukemia</i> , 2020, 34, 1229-1240.	7.2	73
43	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
44	Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma. <i>Cancer Medicine</i> , 2020, 9, 2077-2084.	2.8	17
45	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
46	Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program. <i>Blood</i> , 2020, 136, 15-15.	1.4	5
47	Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better. <i>Clinical Hematology International</i> , 2020, 2, 92.	1.7	2
48	Allogeneic transplant for <i>FLT3</i> - <i>ITD</i> mutated AML: a focus on <i>FLT3</i> inhibitors before, during, and after transplant. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071988266.	2.5	22
49	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47
50	Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2019, 187, e64-e68.	2.5	18
51	Relapsed refractory multiple myeloma: a comprehensive overview. <i>Leukemia</i> , 2019, 33, 2343-2357.	7.2	90
52	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 1815-1826.	2.4	75
53	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1407-1415.	2.0	42
54	Current status of autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 44.	6.2	175

#	ARTICLE	IF	CITATIONS
55	Impact of cyclosporine A concentration on acute graft-versus-host disease incidence after haploidentical hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 10-17.	2.2	17
56	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. <i>Haematologica</i> , 2019, 104, 1682-1688.	3.5	91
57	Cutaneous lupus with Kikuchi disease-like inflammatory pattern associated with myelodysplastic syndrome. <i>Rheumatology</i> , 2019, 58, 554-556.	1.9	1
58	CD34 -selected stem cell "Boost" for poor graft function after allogeneic hematopoietic stem cell transplantation. <i>Current Research in Translational Medicine</i> , 2019, 67, 112-114.	1.8	19
59	IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 1910-1925.	8.2	85
60	Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1471-1475.	2.0	28
61	Biomarkers in chronic graft-versus-host disease: quo vadis?. <i>Bone Marrow Transplantation</i> , 2018, 53, 832-837.	2.4	55
62	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1013-1021.	2.0	59
63	Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. <i>Science Immunology</i> , 2018, 3, .	11.9	93
64	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 127.	17.0	17
65	High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 1493-1497.	2.4	37
66	The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial. <i>Blood</i> , 2018, 132, 1444-1444.	1.4	9
67	Achievement of High Concentration of Cyclosporine-a Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Graft. <i>Blood</i> , 2018, 132, 4565-4565.	1.4	0
68	Arsenic Trioxide Induces Apoptosis and Regulatory Functions of Plasmacytoid Dendritic Cells. <i>Blood</i> , 2018, 132, 514-514.	1.4	0
69	Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	3.5	109
70	Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. <i>Journal of Immunology</i> , 2017, 198, 40-46.	0.8	87
71	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 184-191.	3.5	43
72	Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. <i>Blood</i> , 2017, 130, 2186-2195.	1.4	30

#	ARTICLE	IF	CITATIONS
73	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 278-284.	2.0	38
74	Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2017, 3, 72-81.	4.5	34
75	Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. <i>Cancer Treatment Reviews</i> , 2017, 52, 41-47.	7.7	15
76	Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3993-3995.	1.6	9
77	Evaluation of Infectious Complications after Haploidentical Stem Cell Transplantation in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2017, 130, 664-664.	1.4	3
78	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 906-912.	2.4	364
79	Larger number of invariant natural killer T cells in PBSC allografts correlates with improved CVHD-free and progression-free survival. <i>Blood</i> , 2016, 127, 1828-1835.	1.4	52
80	Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease. <i>Mucosal Immunology</i> , 2016, 9, 299-308.	6.0	20
81	Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease. <i>Cytotherapy</i> , 2015, 17, 948-955.	0.7	9
82	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). <i>Leukemia</i> , 2015, 29, 2375-2381.	7.2	43
83	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2015, 100, 859-869.	3.5	80
84	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2015, 50, 781-789.	2.4	294
85	Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1574-1577.	2.4	23
86	Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. <i>Cancer</i> , 2015, 121, 562-569.	4.1	28
87	High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 620-624.	2.0	33
88	Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study. <i>United European Gastroenterology Journal</i> , 2014, 2, 206-215.	3.8	15
89	18F-FDG PET/CT for the assessment of gastrointestinal CVHD: results of a pilot study. <i>Bone Marrow Transplantation</i> , 2014, 49, 131-137.	2.4	30
90	New Insight for the Diagnosis of Gastrointestinal Acute Graft-versus-Host Disease. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	3.0	30

#	ARTICLE	IF	CITATIONS
91	Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution's Three Decade Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1217-1223.	2.0	39
92	Increased plasmacytoid dendritic cells and ROR $\gamma$ t-expressing immune effectors in cutaneous acute graft-versus-host disease. <i>Journal of Leukocyte Biology</i> , 2013, 94, 1337-1343.	3.3	19
93	IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. <i>Leukemia</i> , 2013, 27, 1527-1537.	7.2	77
94	Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. <i>Leukemia</i> , 2012, 26, 1471-1474.	7.2	46
95	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 314-317.	2.0	42
96	Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2011, 25, 932-938.	7.2	64
97	Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 28-34.	2.0	70